Related references
Note: Only part of the references are listed.Cannabis and multiple sclerosis
Yara Dadalti Fragoso et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
Katja Akguen et al.
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2019)
Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews
Bhasker Amatya et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
Peter Flachenecker et al.
CASE REPORTS IN NEUROLOGY (2018)
Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
Patrick Vermersch et al.
EUROPEAN NEUROLOGY (2016)
Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life
P. Flachenecker et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Overview of MS Spasticity
Carlo Pozzilli
EUROPEAN NEUROLOGY (2014)
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice
Peter Flachenecker et al.
EUROPEAN NEUROLOGY (2014)
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
Uwe K. Zettl et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study
Patrick Vermersch
NEURODEGENERATIVE DISEASE MANAGEMENT (2014)
Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study
Rafael Arroyo et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
Spasticity in multiple sclerosis: results of a patient survey
C. Oreja-Guevara et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
Michael G. Serpell et al.
JOURNAL OF NEUROLOGY (2013)
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?
Raymond J. M. Niesink et al.
Frontiers in Psychiatry (2013)
Epidemiology and clinical assessment of spasticity in multiple sclerosis
D. Bensmail et al.
REVUE NEUROLOGIQUE (2012)
Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain
Henry J. McQuay et al.
PAIN (2008)
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
C. Collin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
E Russo et al.
MEDICAL HYPOTHESES (2006)